Beihao Stem Cell and Regenerative Medicine Research Institute

Beihao Stem Cell and Regenerative Medicine Research Institute is a biotechnology company and research platform founded in 2014 through a strategic collaboration between Peking University and Guanhao Biotech. The institute specializes in the development and clinical translation of regenerative medicine and advanced cell therapies, leveraging proprietary CiPS (Chemically induced Pluripotent Stem cells) and EPS (Extended Pluripotent Stem cells) technologies pioneered by Professor Deng Hongkui. Its portfolio includes a bio-artificial liver system, multi-target CAR-T and CAR-NK therapies, and an industrialized autologous chondrocyte transplantation product for cartilage repair. Beihao also provides large-scale cell banking services for immune and stem cells from its GMP-certified facilities in Guangzhou and maintains a strong focus on treating refractory diseases such as liver failure and cancer.